内皮素受体拮抗剂治疗肺动脉高压进展  

Research advances of endothelin receptor antagonists for treatment of pulmonary arterial hypertension

作　　者：吕剑[1] 解卫平[1] 

机构地区：[1]南京医科大学第一附属医院呼吸内科,210009

出　　处：《国际呼吸杂志》2009年第8期497-500,共4页International Journal of Respiration

基　　金：江苏省自然科学基金资助项目（BK2006246）

摘　　要：肺动脉高压是一种以肺血管阻力升高最终导致右心衰竭的严重的症候群。内皮素在其发生、发展过程中起着重要作用，目前已经认识到内皮素受体拮抗剂对治疗肺动脉高压具有一定疗效，但仍需对其疗效和安全性进行进一步研究。本文将对近年内皮素受体拮抗剂治疗肺动脉高压的研究进展作一综述。Pulmonary arterial hypertension is a serious syndrome characterized by stepping up of the pulmonary vascular resistance and inducing right heart failure in the end. Endothelin plays a significant role in the process. Nowadays many studies have already recognized that endothelin receptor antagonists possess some therapeutic effects to pulmonary artery hypertension. But more therapeutic effects and safeties need further researches. This paper summarizes the research advances on the therapy of endothelin receptor antagonists for pulmonary artery hypertension in recent years

关 键 词：内皮素受体拮抗剂 内皮素 肺动脉高压 

分 类 号：R544.16[医药卫生—心血管疾病]